NovoCure Balance Sheet Health
Financial Health criteria checks 5/6
NovoCure has a total shareholder equity of $393.7M and total debt of $568.0M, which brings its debt-to-equity ratio to 144.3%. Its total assets and total liabilities are $1.1B and $752.6M respectively.
Key information
144.3%
Debt to equity ratio
US$567.99m
Debt
| Interest coverage ratio | n/a |
| Cash | US$921.25m |
| Equity | US$393.70m |
| Total liabilities | US$752.65m |
| Total assets | US$1.15b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NVCR N's short term assets ($1.0B) exceed its short term liabilities ($157.2M).
Long Term Liabilities: NVCR N's short term assets ($1.0B) exceed its long term liabilities ($595.5M).
Debt to Equity History and Analysis
Debt Level: NVCR N has more cash than its total debt.
Reducing Debt: NVCR N's debt to equity ratio has increased from 129.8% to 144.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVCR N has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NVCR N has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 14.6% each year